812-P: The Role of Industry and NIH/Academia in the Clinical Development of GLP-1 Agonists and SGLT2 Inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.2337/db21-812-p
Abstract: GLP-1 agonists and SGLT2 inhibitors are increasingly prescribed as second line agents for type 2 diabetes. However, costs for these drugs are high. Pharmaceutical manufacturers often cite high development costs as a justification for high… read more here.
Keywords: industry; nih academia; agonists sglt2; glp agonists ... See more keywords